anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a preparation of propolis water extract and a water-soluble propolis powder. The invention can be used in medicine, pharmacology, perfumes-cosmetic and the food industry. The method for preparing the propolis water extract consists in the following: the raw propolis undergoes extraction of mineral salts with the aid of a water solution. In the process of extraction, electric current passes through said solution by means of two electrodes. One of the electrodes, the cathode, is made of silver. The 0.5-4.0 g of raw propolis is applied to 1cm2 of the surface of the silver electrode. The electric current passes through the silver electrode during 3-6 hours with an energy-flux density of (1.5-18.0)x 103 A/cm2. The silver electrode subsequently treated with propolis is replaced by an electrode with a clean surface through which the electric current passes once more. The propolis water extracts are cooled. The propolis concentration in the water solution is increased by repeated charging of the raw propolis and by current transmission. The elimination of water from the propolis extract results in the water-soluble propolis powder. The propolis water extract with concentration of less than 2 mas. % can be used as a drink.
Benaglutide will be administered three times a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given 10 minutes before each meal.
Participants will consume a muffin containing 20 g of dietary fat provided by the test oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the test oil and their food intake at an ad libitum meal will be measured 1 hour later.
Sepsis is a major global health problem, causing a significant burden of disease and death worldwide. Risk stratification of sepsis patients, identification of severe patients and timely initiation of treatment can effectively improve the prognosis of sepsis patients. We procured gene expression datasets for sepsis (GSE54514, GSE65682, GSE95233) from the Gene Expression Omnibus and performed normalization to mitigate batch effects. Subsequently, we applied weighted gene co-expression network analysis to categorize genes into modules that exhibit correlation with macrophage activity. To pinpoint macrophage-associated genes (MAAGs), we executed differential expression analysis and single sample gene set enrichment analysis. We then established a prognostic model derived from four MAAGs that were significantly differentially expressed. Functional enrichment analysis and immune infiltration assessments were instrumental in deciphering the biological mechanisms involved. Furthermore, we employed principal component analysis and conducted survival outcome analyses to delineate molecular subgroups within sepsis. Four novel MAAGs-CD160, CX3CR1, DENND2D, and FAM43A-were validated and used to create a prognostic model. Subgroup classification revealed distinct molecular profiles and a correlation with 28-day survival outcomes. The MAAGs risk score was developed through univariate Cox, LASSO, and multivariate Cox analyses to predict patient prognosis. Validation of the risk score upheld its prognostic significance. Functional enrichment implicated ribonucleoprotein complex biogenesis, mitochondrial matrix, and transcription coregulator activity in sepsis, with an immune infiltration analysis indicating an association between MAAGs risk score and immune cell populations. The four MAAGs exhibited strong diagnostic capabilities for sepsis. The research successfully developed a MAAG-based prognostic model for sepsis, demonstrating that such genes can significantly stratify risk and reflect immune status. Although in-depth mechanistic studies are needed, these findings propose novel targets for therapy and provide a foundation for future precise clinical sepsis management.
The invention relates to a mixing tablet, and in particular to a nano-berberine and nano-spirulina mixing tablet. The mixture of the berberine and the spirulina cannot be easily absorbed, and the absorption rate is about 5%. In order to solve the problem, the invention provides the nano-berberine and nano-spirulina mixing tablet. The nano-berberine and nano-spirulina mixing tablet comprises vitamin, the berberine, the spirulina and an auxiliary material. The diameters of the berberine particle and the spirulina particle are the nanoscale. The mass ratio is as follows: 1-3% of the vitamin, 10-20% of the berberine, 25-35% of the spirulina, and the balance of the auxiliary material. The preferential mass ratio is as follows: 2% of the vitamin, 15% of the berberine, 30% of the spirulina, and the balance of the auxiliary material. Trace amounts of selenium is added to the mixing tablet. The absorbability of the vitamin to the human body is very good, so the berberine and the spirulina are absorbed while the vitamin is absorbed through the combination of the berberine, the spirulina and the vitamin. The problem that the berberine and the spirulina are difficulty absorbed can be solved, and the absorption rate is improved over 15%.
A biologically engineered stent for treating patients suffering from acute myocardial infarction/ischemia. The stent is inserted in a vessel upstream to and proximal the damaged muscle/ischemic area. The stent elutes Stromal Derived Factor (SDF1)/CXCR4 complex and /or Vascular Endothelial Growth Factor (VEGF) to attract autologous stem cell for the repair of damaged myocardium or tissues and inducing vascularization (creation of collateral vessels) to the ischemic area. The SDF1/CXCR4 acts as a homing mechanism for stem cells. Stem cell mobilizing agents such as Gm-CSF, GCSF and Plerixafor, as a CXCR4 blocker, may be added systemically to assist in stem mobilization. A protocol consisting of multiple doses of Gm-CSF or GCSF may be given in order to mobilize stem cells from the patient. Optionally, stem cells may be injected into the patient. The treatment stimulates repair and improves survival of damaged myocardium and prevents ventricular remodeling.
Electrodes will be placed in the auricle of the left ear. Electrical stimulation to these electrodes will be provided by a current-constant stimulator (Urostim, Schwa-Medico). Stimulation will be gated, with 1-second delay, after peak inhalation (i.e. during exhalation). Respiratory gating for stimulation will require real-time evaluation of the respiratory cycle. The study will use a belt system constructed in-house, and similar to the system used in several previous studies. A pneumatic belt will be placed around the subject's lower thorax. Once electrodes are set up, subjects will be asked to rate stimulation intensity on a NRS of 0 to 10 (0: no sensation, 10: pain detection threshold). Current intensity will be set to achieve moderate to strong (but not painful) sensation, and this current intensity will be used on subsequent stimulation runs.
Despite significant advances in cancer treatment over the decades, surgical resection remains a prominent management approach for solid neoplasms. Unfortunately, accumulating evidence suggests that surgical stress caused by tumor resection may potentially trigger postoperative metastatic niche formation. Surgical stress not only activates the sympathetic-adrenomedullary axis and hypothalamic-pituitary-adrenocortical axis but also induces hypoxia and hypercoagulable state. These adverse factors can negatively impact the immune system by downregulating immune effector cells and upregulating immune suppressor cells, which contribute to the colonization and progression of postoperative tumor metastatic niche. This review summarizes the effects of surgical stress on four types of immune effector cells (neutrophils, macrophages, natural killer cells and cytotoxic T lymphocytes) and two types of immunosuppressive cells (regulatory T cells and myeloid-derived suppressor cells), and discusses the immune mechanisms of postoperative tumor relapse and progression. Additionally, relevant therapeutic strategies to minimize the pro-tumorigenic effects of surgical stress are elucidated.
BACKGROUND: The origins and timing of inpatient room sink contamination with carbapenem-resistant organisms (CROs) are poorly understood.
METHODS: We performed a prospective observational study to describe the timing, rate, and frequency of CRO contamination of in-room handwashing sinks in 2 intensive care units (ICU) in a newly constructed hospital bed tower. Study units, A and B, were opened to patient care in succession. The patients in unit A were moved to a new unit in the same bed tower, unit B. Each unit was similarly designed with 26 rooms and in-room sinks. Microbiological samples were taken every 4 weeks from 3 locations from each study sink: the top of the bowl, the drain cover, and the p-trap. The primary outcome was sink conversion events (SCEs), defined as CRO contamination of a sink in which CRO had not previously been detected.
RESULTS: Sink samples were obtained 22 times from September 2020 to June 2022, giving 1,638 total environmental cultures. In total, 2,814 patients were admitted to study units while sink sampling occurred. We observed 35 SCEs (73%) overall; 9 sinks (41%) in unit A became contaminated with CRO by month 10, and all 26 sinks became contaminated in unit B by month 7. Overall, 299 CRO isolates were recovered; the most common species were Enterobacter cloacae and Pseudomonas aeruginosa.
CONCLUSION: CRO contamination of sinks in 2 newly constructed ICUs was rapid and cumulative. Our findings support in-room sinks as reservoirs of CRO and emphasize the need for prevention strategies to mitigate contamination of hands and surfaces from CRO-colonized sinks.
A system may include a data processor and a memory storing instructions. The instructions may result in operations when executed by the data processor. The operations may include determining, based on location data from a positioning system, a presence of a cartridge at a location. The cartridge may include a substance. A quantity of the substance may be determined based on content data from a content meter at the location. Diversion of the substance may be detected based on the cartridge being present at the location and/or the quantity of the substance. Related methods and articles of manufacture, including apparatuses and computer program products, are also disclosed.
The invention relates to the technical field of microorganisms, and particularly relates to lactobacillus casei Ma.GLRGJ1 and application thereof. The invention provides Lactobacillus casei (Lactobacillus casei) Ma.GLRGJ1, which is preserved in China general microbiological culture Collection center with the preservation number of CGMCC No. 18922. The lactobacillus casei Ma. GLRGJ1 can tolerate and grow in an acidic environment with the pH value of more than 2.0 and has strong bile salt tolerance; has good effects of inhibiting bacteria and degrading mycotoxin; the lactobacillus casei Ma. GLRGJ1 is prepared into a microbial inoculum and then is used for feeding animals, and has safe and reliable effect and positive effects on promoting digestion and absorption of nutrient substances, improving feed conversion efficiency and promoting growth.
The invention relates to medicine, namely to immunotherapy. Summary of the invention consists in the fact that the monoclonal immunostimulating antibody or the antibody fragment, which binding an antigen, being bound up with the B lymphoblastoid cells, induces the proliferation and activation of the peripheral blood lymphocytes, ensures an antitumorous effect. The proposed antibody is obtained by immunization of the animal with an immunogen from the group consisting of B lymphoblastoid cells, lysed B lymphoblastoid cells and membranous preparations thereof, the subsequent development of the immune reaction to the immunized animals, extraction of B lymphocytes, growing, immortalization and selection of cell lines, secreting the proposed antibody. It is also claimed the Hybridome cell line deposited in the CNCM under No. I-1397. It is proposed a method of disease treatment, including the administration of an efficient amount of the proposed monoclonal immunostimulating antibody. It is claimed a pharmaceutical composition, including in the capacity of an active ingredient the proposed monoclonal immunostimulating antibody. Moreover, the pharmaceutical composition can additionally comprise an agent increasing the activity of cytotoxic lymphocytes. The result consists in the proliferation and activation of lymphocytes, ensuring the antitumorous effect. Claims: 18 Fig.: 10
The invention discloses application of zingiberenone A in preparing foods for preventing cardiovascular diseases and medicines for treating the cardiovascular diseases, and belongs to the technical field of biological medicines. The invention provides an application of zingiberenone A in preparing foods for preventing cardiovascular diseases. The invention can prevent atherosclerosis by preparing Jiang Xitong A-containing food and feeding the food to mice, thereby preventing cardiovascular diseases caused by atherosclerosis. According to the invention, by establishing a rabbit atherosclerosis model, cardiovascular diseases can be effectively relieved after treatment by using the drug containing the zingibenone A. The food and the medicine containing the zingibenone prepared by the invention have remarkable effect on inhibiting the adhesion of vascular endothelial cells and immune cells. Simultaneously can inhibit the expression of VCAM-1 protein, and inhibit the expression of VCAM-1 and MCP-1mRNA, thus having good effect on improving, preventing or treating cardiovascular diseases.
Pancreatitis has been observed in patients receiving KALETRA therapy, including those who developed marked triglyceride elevations. In some cases, fatalities have been observed. Although a causal relationship to KALETRA has not been established, marked triglyceride elevations are a risk factor for development of pancreatitis [see Warnings and Precautions (5.9)]. Patients with advanced HIV-1 disease may be at increased risk of elevated triglycerides and pancreatitis, and patients with a history of pancreatitis may be at increased risk for recurrence during KALETRA therapy.

Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis occur. Patients who exhibit these signs or symptoms should be evaluated and KALETRA and/or other antiretroviral therapy should be suspended as clinically appropriate.
This study is performed in healthy adults, older than 18 years, with no gastro-intestinal complaints. The intervention group receives personalized dietary advice (PDA) based on their current food pattern, preferences and selfregulation capacity. The PDA aims to compute high-fiber alternatives for products that subjects currently use and that are close to their current eating behavior, to help increase dietary fiber intake. This PDA will be provided using an online webportal. The control group only receives a general dietary advice, e.g. (a) flyer(s) containing information on fibers from the Netherlands Nutrition Center and the MLDS. The intervention group will also receive this general advice next to the PDA.
Psychoactive drugs frequently contaminate aquatic environments after human consumption, raising concerns about their residues and ecological harm. This study investigates the effects of flunitrazepam (FLZ) and its metabolite 7-aminoflunitrazepam (7-FLZ), benzodiazepine-class psychoactive drugs, on brain accumulation, blood-brain barrier (BBB), and neuroinflammation of the model organism zebrafish. Molecular dynamics simulation and transcriptome sequencing were used to uncover their toxic mechanisms. Results demonstrate that both FLZ and 7-FLZ can accumulate in the brain, increasing Evans blue levels by 3.4 and 0.8 times, respectively. This increase results from abnormal expression of tight junction proteins, particularly ZO-1 and Occludin, leading to elevated BBB permeability. Furthermore, FLZ and 7-FLZ can also induce neuroinflammation, upregulating TNFα by 91% and 39%, respectively, leading to pathological changes and disrupted intracellular ion balance. Molecular dynamics simulation reveals conformational changes in ZO-1 and Occludin proteins, with FLZ exhibiting stronger binding forces and greater toxicity. Weighted gene co-expression network analysis identifies four modules correlated with BBB permeability and neuroinflammation. KEGG enrichment analysis of genes within these modules reveals pathways like protein processing in the endoplasmic reticulum, NOD-like receptor signaling pathway, and arginine and proline metabolism. This study enhances understanding of FLZ and 7-FLZ neurotoxicity and assesses environmental risks of psychoactive substances. ENVIRONMENTAL IMPLICATION: With the increasing prevalence of mental disorders and the discharge of psychoactive drugs into water, even low drug concentrations (ng/L-μg/L) can pose neurological risks. This study, utilizing molecular dynamic (MD) simulations and transcriptome sequencing, investigate the neurotoxicity and mechanisms of flunitrazepam and 7-aminoflunitrazepam. It reveals that they disrupt the blood-brain barrier in zebrafish and induce neuroinflammation primarily by inducing conformational changes in tight junction proteins. MD simulations are valuable for understanding pollutant-protein interactions. This research offers invaluable insights for the environmental risk assessment of psychoactive drugs and informs the development of strategies aimed at prevention and mitigation.
The estimation of the postmortem interval (PMI) is one of the key challenges for forensic anthropologists. Although there are several methods referenced for this purpose, none is sufficiently effective. One of the main reasons justifying the complexity of this task is the influence of several taphonomic factors.The study of the Luminol technique has stood out as a promising method for estimating PMI, complementing the existing methods, since it is an economic, easy and reproducible method that operates as a presumptive test. However, it is not known which taphonomic factors can influence the results obtained by this technique.The aim of this study is to test the influence of taphonomic factors, such as temperature, humidity, soil type and pH, on the estimation of the PMI by the Luminol technique.In order to test the influence of the referred factors, a sample consisting of 30 clavicles, with known and similar PMI, collected from autopsies, was distributed as evenly as possible by six vases and buried with different decomposition conditions for a period of 12 months. After the exhumation and sample preparation, the Luminol technique was applied.It was possible to clearly observe differences in the results. Thus, according to our research, it is possible to conclude that the results obtained by the application of Luminol are influenced by taphonomic factors. Therefore, the context in which a body is found should always be considered for applying this technique.
Budesonide and formoterol fumarate dihydrate should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD. Budesonide and formoterol fumarate dihydrate has not been studied in patients with acutely deteriorating asthma or COPD. The initiation of budesonide and formoterol fumarate dihydrate in this setting is not appropriate.

Increasing use of inhaled, short-acting beta2-agonists is a marker of deteriorating asthma. In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. Patients should not use more than 2 inhalations twice daily (morning and evening) of budesonide and formoterol fumarate dihydrate.

Budesonide and formoterol fumarate dihydrate should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. An inhaled, short-acting beta2-agonist, not budesonide and formoterol fumarate dihydrate, should be used to relieve acute symptoms such as shortness of breath. 

When beginning treatment with budesonide and formoterol fumarate dihydrate, patients who have been taking oral or inhaled, short-acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.
A composition containing extracts of Allium victorialis subsp. which has anti-inflammation activity is provided to prevent and treat rheumatoid arthritis or atherosclerosis. An extract from Allium victorialis subsp. having antioxidation and anti-inflammation activities is obtained by extracting an Allium victorialis subsp. with ethanol, methanaol, propanol, chloroform, and acetone. The extract of Allium victorialis subsp. Is obtained from leaves or seed of Allium victorialis subsp. A pharmaceutical composition for preventing or treating anti-inflammatory disease contains the extract of Allium victorialis subsp. as an active ingredient. The composition is used in a form of solid formulation such as tablet, powder, pill, granule, and capsule, or parenteral administration such as sterilized solution, suspension, emulsion, and suppository.